Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.47 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9605542 | 0.94 | KDR (0.72) | KDRABCB1ABCG2CARM1 | |
| SCHEMBL9605955 | 0.89 | KDR (0.78) | KDRABCB1ABCG2CARM1 | |
| SCHEMBL14122438 | 0.89 | KDR (0.82) | KDRABCB1ABCG2CARM1 | |
| SCHEMBL9605544 | 0.87 | KDR (0.76) | KDRABCB1ABCG2CARM1 | |
| SCHEMBL14325936 | 0.85 | KDR (0.88) | KDRCARM1 | |
| SCHEMBL9605571 | 0.85 | KDR (1.00) | KDR | |
| SCHEMBL14122430 | 0.85 | KDR (0.87) | KDRABCB1ABCG2CARM1 | |
| SCHEMBL4439008 | 0.84 | KDR (0.80) | KDRABCB1ABCG2CARM1 | |
| SCHEMBL9605545 | 0.83 | KDR (1.00) | KDRABCB1ABCG2CARM1 | |
| SCHEMBL4445915 | 0.83 | KDR (0.68) | KDRABCB1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338455-B2 | Pyridines or pyrimidines having 4-(hydrogenated 1-pyridyl- or hydrogenated 1-isoquinolyl rings, e.g., N-(4-chlorophenyl)-2-(pyridin-4-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-5-carboxamide; kinase inhibitors; inflammation, angiogenesis and cancer | AMGEN INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338455-B2 | Pyridines or pyrimidines having 4-(hydrogenated 1-pyridyl- or hydrogenated 1-isoquinolyl rings, e.g., N-(4-chlorophenyl)-2-(pyridin-4-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-5-carboxamide; kinase inhibitors; inflammation, angiogenesis and cancer | AMGEN INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2118088-B1 | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer | AMGEN INC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20080161346-A1 | Compounds and methods of use | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161346-A1 | Compounds and methods of use | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008079292-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN TREATING INFLAMMATION, ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161346-A1 | Compounds and methods of use | VHL, VEGFA, FLT1 | KDR 6/4885ABCB1 162/4885ABCG2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.